Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma

被引：0
|
作者：
Fatemeh Karimi [1 ]
Mojtaba Aghaei [2 ]
Najmaldin Saki [1 ]
机构：
[1] Ahvaz Jundishapur University of Medical Sciences,
[2] Thalassemia & Hemoglobinopathy Research Center,undefined
[3] Health Research Institute,undefined
[4] Ahvaz Jundishapur University of Medical Sciences,undefined
来源：
Current Treatment Options in Oncology | 2025年 / 26卷 / 3期
关键词：
Polymorphisms; Treatment outcomes; Multiple Myeloma; Genetic markers; Personalized therapy; Biomarkers;
D O I：
10.1007/s11864-025-01295-8
中图分类号：
学科分类号：
摘要：
Multiple myeloma (MM) is a lymphoproliferative disorder that remains a fatal disease despite therapeutic advances.Treatment responses vary among MM patients due to biological factors, tumor characteristics, and genetic differences.Research indicates that genetic polymorphisms, particularly single nucleotide polymorphisms, may influence treatment efficacy and patient outcomes in MM.Ongoing research into these genetic factors may provide valuable insights into the underlying mechanisms of drug efficacy and resistance in this complex disease.
引用
下载
收藏
页码：197 / 212
页数：15
相关论文
共 50 条
  • [31] Proteasome inhibitors and immunomodulatory drugs improve survival in relapsed or progressive multiple myeloma after allogeneic hematopoietic cell transplantation
    Schneidawind, C.
    Duerr-Stoerzer, S.
    Faul, C.
    Kanz, L.
    Weisel, K.
    Bethge, W.
    Schneidawind, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 78 - 78
  • [32] Cardiotoxicity as an Adverse Effect of Immunomodulatory Drugs and Proteasome Inhibitors in Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials
    Das, Avash
    Roy, Bhaskar
    Dasgupta, Subhajit
    Gong, Yan
    Shah, Urvi A.
    Cheng, Richard K.
    Fradley, Michael G.
    Guha, Avirup
    CIRCULATION, 2021, 144
  • [33] MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs
    Knop, Stefan
    Goldschmidt, Hartmut
    Raab, Marc S.
    Szarejko, Monika
    Jurczyszyn, Artur
    Durig, Jan
    Bringhen, Sara
    Gamberi, Barbara
    Vacca, Angelo
    Acosta, Jorge Castellano
    Lemaillet, Guy
    Cortijo, Cedric
    Sudhir, Bansod
    Grzasko, Norbert
    BLOOD, 2018, 132
  • [34] Thrombocytopenia with coagulation abnormality in multiple myeloma patients treated with proteasome inhibitor and/or immunomodulatory drugs
    Suzuki, Kazuhito
    Nishiwaki, Kaichi
    Nagao, Riku
    Katori, Mitsuji
    Fukushima, Ryoko
    Sakayori, Yo
    Masuoka, Hidekazu
    Yano, Shingo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S85 - S86
  • [35] Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study
    Kumar, Shaji
    Dimopoulos, Meletios A.
    Kastritis, Efstathios
    Terpos, Evangelos
    Nahi, Hareth
    Goldschmidt, Hartmut
    Hillengass, Jens
    Leleu, Xavier
    Beksac, Meral
    Alsina, Melissa
    Oriol, Albert
    Cavo, Michele
    Ocio, Enrique M.
    Mateos, Maria Victoria
    O'Donnell, Elizabeth K.
    Vij, Ravi
    Lokhorst, Henk M.
    van de Donk, Niels W. C. J.
    Min, Chang-Ki
    Mark, Tomer
    Turesson, Ingemar
    Hansson, Markus
    Ludwig, Heinz
    Jagannath, Sundar
    Delforge, Michel
    Kyriakou, Charalampia
    Hari, Parameswaran
    Mellqvist, Ulf-Henrik
    Usmani, Saad Z.
    Dytfeld, Dominik
    Badros, Ashraf Z.
    Moreau, Philippe
    Kim, Kihyun
    Otero, Paula Rodriguez
    Lee, Jae Hoon
    Shustik, Chaim
    Waller, Daniel
    Chng, Wee Joo
    Ozaki, Shuji
    Lee, Je-Jung
    de la Rubia, Javier
    Eom, Hyeon Seok
    Rosinol, Laura
    Lahuerta, Juan Jose
    Sureda, Anna
    Kim, Jin Seok
    Durie, Brian G. M.
    BLOOD, 2016, 128 (22)
  • [36] Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
    Kumar, S. K.
    Dimopoulos, M. A.
    Kastritis, E.
    Terpos, E.
    Nahi, H.
    Goldschmidt, H.
    Hillengass, J.
    Leleu, X.
    Beksac, M.
    Alsina, M.
    Oriol, A.
    Cavo, M.
    Ocio, E. M.
    Mateos, M. V.
    O'Donnell, E. K.
    Vij, R.
    Lokhorst, H. M.
    van de Donk, N. W. C. J.
    Min, C.
    Mark, T.
    Turesson, I.
    Hansson, M.
    Ludwig, H.
    Jagannath, S.
    Delforge, M.
    Kyriakou, C.
    Hari, P.
    Mellqvist, U.
    Usmani, S. Z.
    Dytfeld, D.
    Badros, A. Z.
    Moreau, P.
    Kim, K.
    Otero, P. R.
    Lee, J. H.
    Shustik, C.
    Waller, D.
    Chng, W. J.
    Ozaki, S.
    Lee, J-J
    de la Rubia, J.
    Eom, H. S.
    Rosinol, L.
    Lahuerta, J. J.
    Sureda, A.
    Kim, J. S.
    Durie, B. G. M.
    LEUKEMIA, 2017, 31 (11) : 2443 - 2448
  • [37] Audit of thromboprophylaxis for patients with multiple myeloma on treatment with immunomodulatory drugs
    Kumari, A.
    Man, R.
    Gardner, C.
    Paneesha, S.
    Kishore, B.
    Pratt, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 90 - 90
  • [38] Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
    Landgren, Ola
    Sonneveld, Pieter
    Jakubowiak, Andrzej
    Mohty, Mohamad
    Iskander, Karim S.
    Mezzi, Khalid
    Siegel, David S.
    LEUKEMIA, 2019, 33 (09) : 2127 - 2143
  • [39] Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
    Ola Landgren
    Pieter Sonneveld
    Andrzej Jakubowiak
    Mohamad Mohty
    Karim S. Iskander
    Khalid Mezzi
    David S. Siegel
    Leukemia, 2019, 33 : 2127 - 2143
  • [40] Treatment of multiple myeloma with immunomodulatory drugs - thalidomide, lenalidomide and pomalidomide
    Rzepecki, Piotr
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2009, 13 (05): : 265 - 275
12345